위장관 출혈 치료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the gastrointestinal bleeding treatment market size in 2026 is estimated at USD 934.59 million, growing from 2025 value of USD 890 million with 2031 projections showing USD 1.19 billion, growing at 5.01% CAGR over 2026-2031.

This report is Segmented by Product (Endoscopic Mechanical Devices, Endoscopic Thermal Devices, Endoscopic Injection Devices, and More), GI Tract Division (Upper GI Tract, Small Bowel, and Lower GI Tract), End User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Gastrointestinal Bleeding Treatment Market Trends and Insights

Rising Incidence Of Upper GI Bleeding Cases

Upper-GI bleeding rates remain 84-160 per 100,000 adults, with mortality still near 10% despite newer therapies. Anticoagulant uptake in aging cohorts magnifies risk and pushes clinicians to deploy combination hemostasis kits during the index endoscopy to curb costly rebleeds. Hospitals quantify savings when rapid hemostasis avoids surgical conversion, strengthening demand for devices that shorten procedure time and enhance clip retention. Manufacturers therefore package clips, sprays, and injection catheters in modular kits to ensure readiness for any bleeding phenotype. Health systems with capitated payment models increasingly standardize these kits across sites to cut variation and improve outcomes reporting.

Shift Toward Minimally-Invasive Endoscopic Hemostasis

Over-the-scope clips and single-channel suturing systems now seal full-thickness wall defects once referred for open surgery, reducing hospital days and narcotic use. Boston Scientific's OverStitch NXT connects to a standard gastroscope and completes suture patterns in fewer passes, allowing faster turnover in busy labs. Early data show lower 30-day rebleed rates relative to thermal coagulation, especially for fibrotic ulcers. The skill gap, however, necessitates simulation-based upskilling and has opened a parallel market for VR-enabled training modules. Hospitals that couple advanced tools with rigorous credentialing enjoy fewer emergency transfers and better quality scores under pay-for-performance contracts.

Shortage Of Skilled Endoscopists In Emerging Markets

Asia-Pacific adds thousands of endoscopy rooms annually, yet lacks certified staff trained in advanced closure devices, delaying uptake of premium solutions. ESGE recommends objective competence metrics that extend training cycles, placing strain on national budgets and widening urban-rural gaps. Vendors respond with simplified clip applicators and tele-mentoring platforms, but credentialing backlogs persist. Consequently, procurement committees defer purchase of high-end kits until skill pipelines mature, tempering the gastrointestinal bleeding treatment market in lower-income countries.

Other drivers and restraints analyzed in the detailed report include:

1. Availability Of Next-Generation Hemostatic Clips & Sprays
2. Expanding Elderly Population Using Anticoagulants
3. High Cost Of Advanced Endoscopic Devices

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Mechanical clips held 44.74% of the gastrointestinal bleeding treatment market in 2025 thanks to decades-long clinician familiarity and multi-lesion versatility. The segment benefits from continuous miniaturization and stronger grasp forces that cut clip counts per case. The gastrointestinal bleeding treatment market size for topical sprays, though smaller, expands at a 11.9% CAGR because powders address diffuse bleeding and function regardless of coagulation status. Thermal probes and injection catheters maintain niche roles for variceal management and are frequently bundled in combination kits to guarantee first-pass hemostasis.

Performance metrics now focus on deployment speed; Boston Scientific's MANTIS clip requires 4 fewer clips and nearly 5 fewer minutes than predecessors, freeing lab capacity for additional cases. Biocompatible hemostatic agents sourced from algae reduce immunogenicity, opening use in immunosuppressed cohorts. Manufacturers differentiate via pre-loaded, rotation-controlled handle designs and radiopaque markers that aid fluoroscopic confirmation during hybrid procedures.

Complete Report Scope:

• By Product
  • Endoscopic Mechanical Devices
  • Endoscopic Thermal Devices
  • Endoscopic Injection Devices
  • Topical Hemostatic Sprays
  • Combination Therapy Kits
  • Other Products
• By GI Tract Division
  • Upper GI Tract
  • Small Bowel / Mid GI Tract
  • Lower GI Tract
• By End User
  • Hospitals / Clinics
  • Ambulatory Surgical Centers
  • Specialized GI Centers
  • Diagnostic Laboratories
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 40.25% of global revenue in 2025 because Medicare reimburses both inpatient and ASC-based hemostasis, stabilizing cash-flows for providers. U.S. health systems also pilot AI-guided triage that decreases emergency endoscopy wait times and promotes early intervention. Canada's single-payer framework funds national bulk buys of hemostatic powders, ensuring uniform access and driving predictable procurement cycles. Mexico benefits from cross-border medical tourism for endoscopic treatment, particularly among uninsured U.S. patients seeking lower procedure costs.

Asia-Pacific is the fastest-growing region at 8.49% CAGR, reflecting a sharp rise in gastrointestinal cancers and anticoagulant prescriptions. China upgrades county-level hospitals with fluoroscopy suites and capsule endoscopy readers under national health reforms, whereas Japan commercializes robot-assisted suturing platforms that cater to a super-aged population. India's private hospitals expand advanced GI services for an insured middle class and focus on rebleed-avoidance metrics to compete for medical tourists from the Gulf.

Europe posts stable growth, aided by ESGE guidelines that harmonize training and drive collective device purchasing across hospital consortia. Germany pioneers outpatient reimbursement for over-the-scope clips, while the United Kingdom expands rapid-access GI bleed units to meet the National Health Service's 4-hour emergency target. The new EU Medical Device Regulation lengthens approval timelines but lifts public confidence, encouraging hospitals to invest in CE-marked innovations.

The Middle East and Africa plus South America occupy smaller shares yet report double-digit volume growth as tertiary centers open dedicated endoscopy units. High import tariffs remain a hurdle, steering facilities toward multipurpose devices that cover both bleeding and polypectomy use-cases.

1. Boston Scientific
2. Olympus
3. Medtronic
4. Cook Group
5. Conmed
6. Erbe Elektromedizin
7. Ovesco Endoscopy
8. STERIS
9. Pfizer
10. U.S. Medical Innovations
11. Fujifilm Holdings Corp.
12. HOYA Corp. (Pentax Medical)
13. Johnson & Johnson
14. Baxter
15. Teleflex
16. B. Braun
17. Takeda Pharmaceutical Co.
18. Novo Nordisk
19. Smiths Group
20. Ferring Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence Of Upper GI Bleeding Cases
  • 4.2.2 Shift Toward Minimally-Invasive Endoscopic Hemostasis
  • 4.2.3 Availability Of Next-Generation Hemostatic Clips & Sprays
  • 4.2.4 Expanding Elderly Population Using Anticoagulants
  • 4.2.5 AI-Driven Bleeding-Risk Prediction Algorithms
  • 4.2.6 Hospital Incentives For 24/7 GI-Bleed Response Teams
• 4.3 Market Restraints
  • 4.3.1 Shortage Of Skilled Endoscopists In Emerging Markets
  • 4.3.2 High Cost Of Advanced Endoscopic Devices
  • 4.3.3 Supply-Chain Bottlenecks In Specialty Metals & Powders
  • 4.3.4 Antimicrobial-Stewardship Limits On Prophylactic PPIs
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Endoscopic Mechanical Devices
  • 5.1.2 Endoscopic Thermal Devices
  • 5.1.3 Endoscopic Injection Devices
  • 5.1.4 Topical Hemostatic Sprays
  • 5.1.5 Combination Therapy Kits
  • 5.1.6 Other Products
• 5.2 By GI Tract Division
  • 5.2.1 Upper GI Tract
  • 5.2.2 Small Bowel / Mid GI Tract
  • 5.2.3 Lower GI Tract
• 5.3 By End User
  • 5.3.1 Hospitals / Clinics
  • 5.3.2 Ambulatory Surgical Centers
  • 5.3.3 Specialized GI Centers
  • 5.3.4 Diagnostic Laboratories
  • 5.3.5 Other End Users
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Boston Scientific Corporation
  • 6.3.2 Olympus Corporation
  • 6.3.3 Medtronic PLC
  • 6.3.4 Cook Group (Cook Medical)
  • 6.3.5 CONMED Corporation
  • 6.3.6 ERBE Elektromedizin GmbH
  • 6.3.7 Ovesco Endoscopy AG
  • 6.3.8 STERIS PLC
  • 6.3.9 Pfizer Inc.
  • 6.3.10 US Medical Innovations
  • 6.3.11 Fujifilm Holdings Corp.
  • 6.3.12 HOYA Corp. (Pentax Medical)
  • 6.3.13 Johnson & Johnson (Ethicon)
  • 6.3.14 Baxter International Inc.
  • 6.3.15 Teleflex Incorporated
  • 6.3.16 B. Braun Melsungen AG
  • 6.3.17 Takeda Pharmaceutical Co.
  • 6.3.18 Novo Nordisk A/S
  • 6.3.19 Smith & Nephew plc
  • 6.3.20 Ferring Pharmaceuticals

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment